Clinical Trials Browser

Phase 2/3 × Stomach Neoplasms × Epirubicin × Clear all

NCT01924819 2025-03-04

TOPGEAR

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Phase 2/3 Completed

Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms